We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gravitational Shunt Valve Offers Flexible Treatment Options

By HospiMedica International staff writers
Posted on 12 Mar 2013
An adjustable gravitational shunt valve allows surgeons to provide a range of treatment options for hydrocephalus patients. More...


The Miethke proSA gravitational valve provides resistance to cerebral spinal fluid (CSF) flow in the upright position. Implanted in combination with fixed or adjustable valves, the proSA allows surgeons to provide patients with distinctly different pressure settings for the lying and the upright positions, thereby reducing the symptoms that are experienced when the intracranial pressure (ICP) is too low, or conversely, too high. By allowing the upright pressure to be managed independently from the lying pressure, the need to find a setting between optimal lying and standing pressures is eliminated, reducing patient symptoms and allowing them to lead as close to a symptom-free life as possible.

The wide adjustability range (from 0–40 cmH2O) enables surgeons to manage the needs of a wide selection of patient types or patient needs, such as height or weight changes. Resistance can be reduced to zero if a gravitational valve is not needed, or increased if more resistance is required. The maximum setting of 40 cmH2O, when combined with a fixed or adjustable valve, gives surgeons the highest opening pressure available for the upright positions. An integrated Active-Lock magnetic-resonance (MR) brake helps prevent the valve from inadvertent pressure adjustments in 1.5 T and 3 T MRI scanners, and the need for readjustments after an MRI. The Miethke proSA gravitational valve is a product of Christoph Miethke (Potsdam, Germany).

“More important than anything is the need for us to understand our customer’s situation and the situation of the patient,” said Christoph Miethke, president and head of research & development at Christoph Miethke. “proSA is a solution to the difficult situations faced by both the surgeon and the patient.”

Effectively maintaining a patient’s CSF drainage to keep ICP within normal physiological ranges is a challenging aspect of managing a Hydrocephalus patient’s condition since CSF tends to drain faster when a patient is standing. This causes a decrease in ICP, which results in headaches, nausea, and other debilitating symptoms. This necessitates the need for higher valve resistance in upright positions, and the taller the patient, the higher the necessary resistance.

Related Links:

Christoph Miethke



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.